We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina Introduces Universal Real-Time PCR Reagent Portfolio
Product News

Illumina Introduces Universal Real-Time PCR Reagent Portfolio

Illumina Introduces Universal Real-Time PCR Reagent Portfolio
Product News

Illumina Introduces Universal Real-Time PCR Reagent Portfolio


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Illumina Introduces Universal Real-Time PCR Reagent Portfolio"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. has launched its real-time PCR reagent portfolio, including a novel, probe-based chemistry for gene expression analysis called NūPCR™.

In addition to the NuPCR Reagents, Illumina announced qPCR DNA Binding Dye (DBD) Assays for Gene Expression Analysis and qPCR High Resolution Melting (HRM) Assays for genotyping studies, providing researchers with a trio of high-quality, budget-friendly options in the qPCR reagent market.

NuPCR is a novel probe-based qPCR technology that is designed to show improved specificity and sensitivity to complex gene targets, as compared to existing qPCR technologies on the market.

Leveraging the power of DesignStudio™, a personalized, web-based design tool available to Illumina customers, NuPCR allows researchers the ability to quickly build custom multiplexed assays.

This unique, easy-to-use software delivers bioinformatically optimized assays, ensuring high PCR efficiencies and assays that work the first time without tedious trial and error optimization.

In addition, NuPCR, DBD, and HRM assays are compatible with any real-time PCR instrument platform, offering researchers a wider range of reagent choices to implement on their existing instrumentation.

“Illumina is excited to offer these high-quality reagents at a disruptive price point. Now customers can perform more experiments with their current resources and on any platform,” said Mark Lewis, Senior Vice President and General Manager, Molecular Biology and PCR Business, Illumina.

Lewis continued, “By combining these reagents with our current real-time PCR instrument, Eco™, Illumina is also now able to provide customers with a complete real-time PCR solution.”

According to Randal J. Kaufman, Ph.D., Director of Degenerative Disease Research at Sanford-Burnham Medical Research Institute, “Real-time PCR methodology is integral to our research and thus, we were very excited to learn about Illumina’s NuPCR technology. DesignStudio makes it easy to design and order probes, especially for our multiplex reactions.”

Dr. Kaufman, an early access customer, added, “We anticipate the product’s quality, lower cost and simplified multiplexing will yield substantial savings over other probe-based technologies.”

Illumina NuPCR reagents, DBD assays, and HRM assays are available through Illumina’s extensive international distributor network. Availability of NuPCR in the United States will be announced in the near future.

Advertisement